# Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

> **NCT01030432** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 285 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** BMS-650032
- **DRUG:** BMS-650032
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Peginterferon Alfa-2a
- **DRUG:** Peginterferon Alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01030432
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030432, "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01030432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*